← Japan catalog ← 4503 Manual 4507 → ← 4503 Pharmaceuticals 4507 →
4506 · Sumitomo Pharma
This is a quantitative scorecard. The numbers below are read directly from Sumitomo Pharma’s EDINET filing, in yen. The Japanese-language narrative, what the business does, its risks, what changed this year, is not machine-read here, so we do not paraphrase it. Find it on EDINET (code 4506) →
The record
What the business has done across the cycle, read straight from the EDINET filing: the multi-year record, and the walk from reported profit to the cash an owner could take out.
The record, 2017–2026
realized figures from each filing · older years to the left| 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | 2026’26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| ¥408.4B | ¥466.8B | ¥459.3B | ¥482.7B | ¥516.0B | ¥560.0B | ¥555.5B | ¥314.6B | ¥398.8B | ¥453.3B | RevenueRevenue |
| — | — | — | 73% | 73% | — | — | — | 62% | 57% | Gross marginGross mgn |
| — | — | — | 32% | 37% | — | — | — | 45% | 36% | SG&A / revenueSG&A/rev |
| — | — | — | 8% | 7% | — | — | — | 7% | 7% | R&D / revenueR&D/rev |
| ¥89.8B | ¥88.2B | ¥57.9B | ¥83.2B | ¥71.2B | ¥60.2B | (¥77.0B) | (¥354.9B) | ¥28.8B | ¥107.3B | Operating incomeOp. inc. |
| 22.0% | 18.9% | 12.6% | 17.2% | 13.8% | 10.8% | −13.9% | −112.8% | 7.2% | 23.7% | Operating marginOp. mgn |
| ¥31.3B | ¥53.4B | ¥48.6B | ¥40.8B | ¥56.2B | ¥56.4B | (¥74.5B) | (¥315.0B) | ¥23.6B | ¥106.9B | Net incomeNet inc. |
| Cash flow & returns | ||||||||||
| ¥19.1B | ¥93.4B | ¥48.7B | ¥46.1B | ¥135.6B | ¥31.2B | ¥11.9B | (¥241.9B) | ¥16.5B | ¥71.7B | Operating cash flowOp. cash |
| — | ¥12.9B | ¥14.0B | ¥17.4B | ¥22.7B | ¥38.3B | ¥41.3B | ¥37.8B | ¥25.6B | ¥20.8B | DepreciationDeprec. |
| (¥12.2B) | ¥27.1B | (¥13.9B) | (¥12.0B) | ¥56.7B | (¥63.5B) | ¥45.2B | ¥35.3B | (¥32.7B) | (¥55.9B) | Working capital & otherWC & other |
| — | ¥5.1B | ¥9.3B | ¥7.7B | ¥6.0B | ¥7.3B | ¥8.5B | ¥10.8B | ¥8.5B | ¥4.6B | CapexCapex |
| — | 1.1% | 2.0% | 1.6% | 1.2% | 1.3% | 1.5% | 3.4% | 2.1% | 1.0% | Capex / revenueCapex/rev |
| — | ¥88.3B | ¥39.4B | ¥38.4B | ¥129.6B | ¥23.9B | ¥3.5B | (¥252.7B) | ¥8.0B | ¥67.1B | Owner earningsOwner earn. |
| — | 18.9% | 8.6% | 8.0% | 25.1% | 4.3% | 0.6% | −80.3% | 2.0% | 14.8% | Owner earnings marginOE mgn |
| — | ¥88.3B | ¥39.4B | ¥38.4B | ¥129.6B | ¥23.9B | ¥3.5B | (¥252.7B) | ¥8.0B | ¥67.1B | Free cash flowFCF |
| — | 18.9% | 8.6% | 8.0% | 25.1% | 4.3% | 0.6% | −80.3% | 2.0% | 14.8% | Free cash flow marginFCF mgn |
| ¥7.2B | ¥7.9B | ¥11.1B | ¥13.1B | ¥11.1B | ¥11.1B | ¥11.1B | ¥2.8B | ¥3M | ¥2M | Dividends paidDiv. paid |
| ¥3M | ¥2M | ¥6M | ¥3M | ¥2M | ¥2M | ¥1M | ¥0 | ¥0 | ¥2M | BuybacksBuybacks |
| 16% | 20% | 12% | 14% | 9% | 7% | -12% | -108% | 6% | 20% | ROICROIC |
| 8% | 12% | 10% | 8% | 10% | 9% | -18% | -202% | 14% | 37% | Return on equityROE |
| 6% | 10% | 8% | 5% | 8% | 7% | −21% | −204% | 14% | 37% | Retained to equityRetained/eq |
| Balance sheet | ||||||||||
| ¥40.8B | ¥147.8B | ¥137.3B | ¥101.7B | ¥193.7B | ¥203.0B | ¥143.5B | ¥29.0B | ¥23.1B | ¥44.3B | Cash & investmentsCash+inv |
| ¥74.1B | ¥113.0B | ¥118.8B | ¥134.5B | ¥135.9B | ¥151.4B | ¥95.9B | ¥81.0B | ¥74.8B | ¥131.4B | ReceivablesReceiv. |
| ¥33.8B | ¥34.2B | ¥35.0B | ¥45.7B | ¥49.6B | ¥40.3B | ¥39.4B | ¥43.7B | ¥37.7B | ¥48.4B | InventoryInvent. |
| — | ¥58.7B | ¥49.2B | ¥62.3B | ¥64.6B | ¥46.2B | ¥52.1B | ¥67.7B | ¥38.5B | ¥56.7B | Accounts payablePayables |
| ¥107.9B | ¥88.5B | ¥104.6B | ¥118.0B | ¥120.8B | ¥145.5B | ¥83.2B | ¥57.0B | ¥74.0B | ¥123.1B | Operating working capitalOper. WC |
| ¥246.1B | ¥348.6B | ¥373.3B | ¥364.1B | ¥459.8B | ¥499.5B | ¥381.9B | ¥269.6B | ¥253.2B | ¥279.3B | Current assetsCur. assets |
| ¥101.1B | ¥68.8B | ¥56.8B | ¥336.9B | ¥82.9B | ¥77.6B | ¥151.6B | ¥365.3B | ¥85.8B | ¥129.1B | Current liabilitiesCur. liab. |
| 2.4× | 5.1× | 6.6× | 1.1× | 5.5× | 6.4× | 2.5× | 0.7× | 3.0× | 2.2× | Current ratioCurr. ratio |
| — | ¥95.1B | ¥99.3B | ¥173.5B | ¥176.5B | ¥195.1B | ¥209.4B | ¥199.8B | ¥197.4B | ¥211.1B | GoodwillGoodwill |
| ¥779.1B | ¥809.7B | ¥834.7B | ¥1.26T | ¥1.31T | ¥1.31T | ¥1.13T | ¥907.5B | ¥742.6B | ¥804.6B | Total assetsAssets |
| ¥68.0B | ¥47.4B | ¥30.9B | ¥25.0B | ¥263.9B | ¥244.0B | ¥244.1B | ¥133.4B | ¥259.0B | ¥179.1B | Total debtDebt |
| ¥27.2B | (¥100.4B) | (¥106.4B) | (¥76.7B) | ¥70.2B | ¥41.0B | ¥100.7B | ¥104.3B | ¥235.9B | ¥134.7B | Net debt / (cash)Net debt |
| 109.2× | 15.4× | 279.6× | 29.1× | 27.5× | 19.7× | -24.4× | -83.0× | 2.1× | 10.5× | Interest coverageInt. cov. |
| ¥412.3B | ¥452.7B | ¥498.1B | ¥532.7B | ¥580.6B | ¥607.9B | ¥406.7B | ¥156.1B | ¥169.5B | ¥292.5B | Shareholders’ equityEquity |
| Per share | ||||||||||
| 398M | 398M | 398M | 398M | 398M | 398M | 398M | 398M | 398M | 398M | Shares out (diluted)Shares |
| ¥1026.28 | ¥1173.25 | ¥1154.23 | ¥1213.20 | ¥1296.69 | ¥1407.48 | ¥1396.19 | ¥790.55 | ¥1002.34 | ¥1139.22 | Revenue / shareRev/sh |
| ¥78.70 | ¥134.33 | ¥122.21 | ¥102.42 | ¥141.29 | ¥141.78 | ¥-187.26 | ¥-791.58 | ¥59.40 | ¥268.57 | EPS (diluted)EPS |
| — | ¥221.89 | ¥99.14 | ¥96.52 | ¥325.59 | ¥60.05 | ¥8.72 | ¥-634.99 | ¥20.11 | ¥168.65 | Owner earnings / shareOE/sh |
| — | ¥221.89 | ¥99.14 | ¥96.52 | ¥325.59 | ¥60.05 | ¥8.72 | ¥-634.99 | ¥20.11 | ¥168.65 | Free cash flow / shareFCF/sh |
| ¥17.97 | ¥19.96 | ¥27.95 | ¥32.94 | ¥27.95 | ¥27.96 | ¥27.96 | ¥7.02 | ¥0.01 | ¥0.01 | Dividends / shareDiv/sh |
| — | ¥12.89 | ¥23.28 | ¥19.41 | ¥15.20 | ¥18.46 | ¥21.28 | ¥27.07 | ¥21.36 | ¥11.58 | Cap. spending / shareCapex/sh |
| ¥1036.11 | ¥1137.78 | ¥1251.92 | ¥1338.70 | ¥1459.09 | ¥1527.74 | ¥1022.24 | ¥392.22 | ¥425.93 | ¥735.03 | Book value / shareBVPS |
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +1.2%/yr | −2.6%/yr |
| Owner earnings / share | −3.4%/yr (8-yr) | −12.3%/yr |
| EPS | +14.6%/yr | +13.7%/yr |
| Dividends / share | −59.7%/yr | −82.2%/yr |
| Capital spending / share | −1.3%/yr (8-yr) | −5.3%/yr |
| Book value / share | −3.7%/yr | −12.8%/yr |
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2026 the business reported ¥106.9B of profit but ¥67.1B of owner earnings: ¥39.8B less than the profit line, taken out by capital spending and the timing of cash.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Reported net income | ¥106.9B | ¥23.6B | (¥315.0B) | (¥74.5B) | ¥56.4B |
| Depreciation & amortizationnon-cash charge added back | +¥20.8B | +¥25.6B | +¥37.8B | +¥41.3B | +¥38.3B |
| Working capital & othertiming of cash in and out, other non-cash items | −¥55.9B | −¥32.7B | +¥35.3B | +¥45.2B | −¥63.5B |
| Cash from operations | ¥71.7B | ¥16.5B | (¥241.9B) | ¥11.9B | ¥31.2B |
| Capital expenditurecash put back in to keep running and to grow | −¥4.6B | −¥8.5B | −¥10.8B | −¥8.5B | −¥7.3B |
| Owner earnings | ¥67.1B | ¥8.0B | (¥252.7B) | ¥3.5B | ¥23.9B |
| Owner-earnings marginowner earnings ÷ revenue | 15% | 2% | -80% | 1% | 4% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Much of fiscal 2026's profit didn't arrive as operating cash; it sits in “working capital & other” above. That can be a real inventory or timing swing, or profit that doesn't run through operating cash at all: a heavy tax year, equity-method earnings, or investment income booked through investing. For a year like this, owner earnings understates the cash earned; the full cash-flow statement carries the rest.
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, and stewardship. The same checks the US pages run, in yen.
Owner’s Scorecard
Will it survive?
- Can it pay its interest? 10.5×ComfortableOperating income ¥107.3B ÷ interest expense ¥10.2B
What this means
Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.
- How heavy is the debt, net of cash? ¥134.7B · 1.3× operating profitModest net debtCash ¥44.3B − debt ¥179.1B
What this means
Netting ¥44.3B of cash and short-term investments against ¥179.1B of debt leaves ¥134.7B owed, about 1.3× a year's operating profit (1.7× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 106 + DIO 90 − DPO 105 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Solid through the cycle10-yr median, range -108%–20%; 20% latest = NOPAT ¥84.8B ÷ invested capital ¥427.2BIndustry peers: median 18%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran 20% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Solid through the cycle9-yr median margin, range -80%–25%; latest ¥67.1B = operating cash ¥71.7B − maintenance capex ¥4.6BIndustry peers: median 11%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 15% of revenue this year, a 8% median across 9 years.
- Mostly cash-backedCash from ops ¥71.7B ÷ net income ¥106.9B
What this means
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Reinvests most of itDividends + buybacks ¥4M ÷ Owner Earnings ¥67.1B
What this means
Of ¥67.1B Owner Earnings, ¥4M (0%) went back to shareholders, ¥2M dividends, ¥2M buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.
- Investing or harvesting? 0.22×HarvestingCapex ¥4.6B ÷ depreciation ¥20.8B
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Durability & moat, 2017–2026
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 8 of 10
What this means
Lost money in 2 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 3 of 10 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 18% → −27% (3-yr avg ends)
What this means
The recent-years average (−27%) sits below the early years (18%), but the latest year (24%) is back near the early level: a cyclical trough dragging the window down, not a one-way slide. The through-cycle median is 13% — read it across the cycle, not on the dip.
- Reinvestment, incremental ROIC returns capital
What this means
The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.
- Owner earnings growth −6%/yr
What this means
Owner earnings shrank about 6% a year over the record.
- Worst year 2024 · −112.8% op. margin
What this means
Operations went underwater in 2024, understand why before trusting the good years.
- Share count +0.0%/yr
What this means
Roughly flat share count, little dilution, little buyback.
- Dividend record paid
What this means
Paid a dividend in 10 of the years on record.
All figures as filed; the source filing is linked above.
How the cash was used, 2018–2026
Over the record, the business generated ¥213.4B of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.
- Reinvested¥67.9B · 32%
- Dividends¥68.3B · 32%
- Buybacks¥18M · 0%
- Retained (debt / cash)¥77.1B · 36%
- Returned to owners¥68.4B
47% of the owner earnings the business produced over the span, ¥68.3B as dividends and ¥18M as buybacks.
- Source of fundingOperating cash
Operating cash covered reinvestment and returns; over the span debt rose ¥131.7B and cash and short-term investments fell ¥103.5B.
- Average price paid for buybacks—
Buybacks ran ¥18M over the span, but the filings don't tag the share count needed to deduce the average price paid.
- Net change in share count0.0%
The diluted count barely moved (398M to 398M): buybacks roughly offset the stock issued to staff.
- Dividend record¥0.01/sh
Paid in 9 of the years on record, the per-share dividend shrinking about 65% a year. It was cut at least once along the way.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Inverting the record
Invert: instead of why Sumitomo Pharma is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2017–2026.
2 of the 5 tests turned up something to look into; the other 3 came back clean.
- Look hereDid debt outgrow the business?¥68.0B → ¥179.1B
Debt rose from ¥68.0B to ¥179.1B while owner earnings went from about ¥55.4B to (¥59.2B): the borrowing grew and the earnings that would carry it are not there now. Debt raised for buybacks or deals rather than growth is the kind that bites in a downturn.
- Look hereDid receivables and inventory outpace sales?26% → 40% of sales
Receivables and inventory grew from ¥107.9B to ¥179.8B while revenue grew 11%: working capital is climbing faster than sales (26% of revenue then, 40% now). That can mean customers paying slower, stock building up, or revenue pulled forward. The filing's cash-flow and receivables notes say which.
- Is it less profitable than it was?
- Did the share count rise anyway?
- Did reported profit become cash?
Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.
The price
What a price would have to assume, set against the record above.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Sumitomo Pharma has delivered.
Sumitomo Pharma’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.
Through the cycle, Sumitomo Pharma earns about ¥36.1B on its 8.0% median owner-earnings margin. This year’s 14.8% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.
—
9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings ¥67.1B on 398M diluted shares; net debt ¥134.7B. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Figures from EDINET, the Financial Services Agency’s disclosure system, the same kind of filing the US pages draw from EDGAR. A separate pool: these names never pass through the US industry classifier.
Manual order: ← 4503 its page in the Manual 4507 →
Industry order: ← 4503 the Pharmaceuticals chapter 4507 →